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Context: The X-linked immunoglobulin superfamily, member 1 (IGSF1), gene is highly expressed 
in the hypothalamus and in pituitary cells of the POU1F1 lineage. Human loss-of-function 
mutations in IGSF1 cause central hypothyroidism, hypoprolactinemia, and macroorchidism. 
Additionally, most affected adults exhibit higher than average IGF-1 levels and anecdotal 
reports describe acromegaloid features in older subjects. However, somatotrope function has 
not yet been formally evaluated in this condition.
Objective: We aimed to evaluate the role of IGSF1 in human and murine somatotrope function.
Patients, Design, and Setting: We evaluated 21 adult males harboring hemizygous IGSF1 loss-
of-function mutations for features of GH excess, in an academic clinical setting.
Main Outcome Measures: We compared biochemical and tissue markers of GH excess in 
patients and controls, including 24-hour GH profile studies in 7 patients. Parallel studies were 
undertaken in male Igsf1-deficient mice and wild-type littermates.
Results: IGSF1-deficient adult male patients demonstrated acromegaloid facial features 
with increased head circumference as well as increased finger soft-tissue thickness. Median 
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serum IGF-1 concentrations were elevated, and 24-hour GH profile studies confirmed 2- to 
3-fold increased median basal, pulsatile, and total GH secretion. Male Igsf1-deficient mice 
also demonstrated features of GH excess with increased lean mass, organ size, and skeletal 
dimensions and elevated mean circulating IGF-1 and pituitary GH levels.
Conclusions: We demonstrate somatotrope neurosecretory hyperfunction in IGSF1-deficient 
humans and mice. These observations define a hitherto uncharacterized role for IGSF1 in 
somatotropes and indicate that patients with IGSF1 mutations should be evaluated for long-
term consequences of increased GH exposure. (J Clin Endocrinol Metab 105: e70–e84, 2020)
Key Words:  pituitary, IGSF1, growth hormone, congenital hypopituitarism
IGSF1 encodes a transmembrane immunoglobulin superfamily glycoprotein that is highly expressed in 
the Rathke pouch (the developing pituitary primor-
dium), adult anterior pituitary cells, and the hypothal-
amus. X-linked, loss-of-function mutations in IGSF1 
result in a variable spectrum of anterior pituitary dys-
function, which is most pronounced in affected males, 
resulting almost universally in mild to moderate con-
genital central hypothyroidism (CCeH). Additionally, 
affected boys generally exhibit discordant pubertal de-
velopment with delayed testosterone rise and growth 
spurt, but normal or precocious onset of testicular 
growth and subsequent postpubertal macroorchidism. 
Hypoprolactinemia also affects 60% of cases (1–3). 
Heterozygous female mutation carriers may demon-
strate no overt endocrinopathies; however, up to 20% 
heterozygotes also exhibit CCeH or hypoprolactinemia, 
and an association with delayed menarche has also been 
reported (3, 4).
IGSF1 undergoes cotranslational proteolysis such 
that only its carboxy-terminal domain (CTD) is traf-
ficked to the plasma membrane (5). Disease-associated 
IGSF1 mutations include entire gene deletions as well 
as missense, nonsense, and frameshift mutations princi-
pally in the part of the gene encoding the CTD. Intragenic 
mutations usually impair trafficking and membrane lo-
calization of the CTD when assessed by overexpression 
in heterologous cells (1, 3).
Although crucial for normal pituitary hormone pro-
duction, the physiological and molecular role of IGSF1 
remains to be elucidated. In this regard, 2 different 
Igsf1-deficient mouse models (Igsf1∆exon1 and Igsf1∆312) 
have yielded valuable functional insights. Males of 
both strains exhibit CCeH, decreased expression of 
thyrotropin-releasing hormone receptor 1 (Trhr1) 
mRNA in their pituitary, and impaired responsiveness 
to thyrotropin-releasing hormone (TRH). These results 
support a mechanistic role for impaired TRH action in 
the pathogenesis of CCeH (1, 6).
Somatotrope function has not yet been formally 
evaluated in IGSF1 deficiency; however, existing data 
suggest that there may be a complex perturbation of GH 
homeostasis. In humans harboring hemizygous IGSF1 
mutations, partial transient GH deficiency occurs in 
16% of boys. However, in adulthood, IGF-1 levels usu-
ally rise above the mean and are anecdotally associated 
with acromegaloid facial features consistent with GH 
excess (3, 4). Igsf1-deficient male mice exhibit increased 
body mass, but body composition has not been evalu-
ated to establish whether lean mass, organ size, and 
skeletal dimensions are also increased, as predicted for 
a GH-mediated effect (1). A lack of robust antihuman 
IGSF1 antibodies precludes characterization of IGSF1 
expression in human pituitary; therefore, protein ex-
pression studies have been undertaken in rodents. 
Studies in mice and rats using a custom IGSF1 antibody 
detected IGSF1 expression in all cells of the POU1F1 
lineage, including somatotropes, consistent with a role 
for IGSF1 in GH production (1, 7). These results are 
substantiated by recent single-cell RNA sequencing data 
from adult male mouse pituitaries (8).
We evaluated somatotrope function in male IGSF1-
deficient humans and mice, profiling GH secretion, 
delineating GH expression in murine pituitary, and 
quantifying peripheral GH-mediated effects in both spe-
cies. Our data demonstrate somatotrope neurosecretory 
hyperfunction in both species, with associated end-
organ sequelae of GH excess.
Materials and Methods
Study approval
Investigations were undertaken with Research Ethics 
Committee approval (Leiden University Medical Center, 
P13.008) with prior written, informed consent and/or were 
clinically indicated. Mouse studies were regulated under 
the Animals (Scientific Procedures) Act 1986 Amendment 
Regulations 2012 following ethical review by the University 
of Cambridge Animal Welfare and Ethical Review Body (UK 
Home Office License no.  80/2098) or conducted in accord-
ance with federal and institutional guidelines with approval of 
the Goodman Cancer Centre Facility Animal Care Committee, 
McGill University (protocol no. 5204).
doi:10.1210/clinem/dgz093 https://academic.oup.com/jcem  e71
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IGSF1-deficient patient cohort
Clinical studies were performed in the Leiden University 
Medical Center and Addenbrooke’s Hospital, Cambridge. 
General auxological and physiological features of GH 
hypersecretion have been evaluated in a previously pub-
lished cohort of 69 male patients (3). All individuals har-
bored hemizygous IGSF1 mutations defined as pathogenic on 
the basis of associated CCeH, phenotype-genotype segrega-
tion, and in silico and in vitro characterization (3). Treatment 
with levothyroxine was used in 89% of boys and 44% of 
adult males.
For the current study, 21 adult males from this cohort were 
recruited from the Netherlands and the United Kingdom for 
targeted evaluation of GH excess and its associated sequelae 
using clinical assessment and direct questioning. This cohort 
will be referred to henceforth as the targeted cohort; their 
characteristics are summarized in Table 1. All 21 patients had 
CCeH (16 were taking levothyroxine), 10 of 21 were prolactin 
deficient, 1 had received rhGH for GH deficiency, and most 
had exhibited delayed pubertal development, for which 1 still 
received testosterone replacement. Cortisol levels were normal 
and testosterone mildly decreased in 2 of 21 cases. Their ages 
ranged from 19 to 89 years (median age, 55.1 years; P10-P90, 
21.8-85.2 years) and the age distribution was skewed toward 
the older part of the range (Shapiro-Wilk test P = 0.015).
Seven Dutch IGSF1-deficient adult males from this cohort 
consented to more detailed evaluation of 24-hour GH secre-
tion patterns. These individuals were selected on the basis of 
their ability to attend Leiden University Medical Center for 
these studies and their willingness to undertake this inten-
sive sampling regimen. These 7 adult male patients exhib-
ited similar phenotypic characteristics and endocrinopathies 
(hypoprolactinemia, levels of IGF-1 and testosterone) to adult 
male patients in the targeted cohort of 21 males, and their 
characteristics are summarized in Table 2. In 1 (patient 7), a 
TRH test with measurement of GH was available, showing a 
paradoxical GH response. All patients had CCeH, 5 of 7 were 
on levothyroxine replacement, with mean FT4 11.3  ±  4.3 
pmol/L. None had recently taken transmeridianal flights or 
carried out night shift work and all patients did not smoke. 
GH secretion patterns were compared with available data 
using 2 age- and body mass index (BMI)-matched healthy 
male control subjects per patient, sampled using the same 
protocol and exclusion criteria (15–17).
To have a larger dataset with children and adults for ana-
lyses of head circumference and IGF-1, we combined data 
from the targeted cohort with available data from the large 
previously published cohort for these parameters. This en-
abled us to assess correlations between head circumference 
and thyroid function in 41 cases aged 0.4 to 89.5  years 
and demonstrate differences between childhood and adult 
IGF-1 standard deviation scores (SDS) in 55 cases aged 0.2 
to 88  years. In addition, TRH tests with measurement of 
GH at baseline, and at 20 and 60 minutes after 200 μg of 
IV Protirelin (TRH, Alliance Pharmaceuticals Ltd, UK) per-
formed in 8 members of the targeted cohort were supple-
mented with available data of 4 patients from the previously 
published cohort.
Clinical and biochemical measurements were compared 
with reference values either obtained from published litera-
ture or generated locally from control subjects. Assessment 
included anthropomorphology (18–20), endocrine biochem-
ical evaluation using early morning samples, measured in 
locally available assays, ultrasonographically measured 
testicular size (21), and BMI- and height-corrected bioelec-
trical impedance analysis of body composition (22) using 
the Bodystat 1500MDD (Bodystat Limited, Douglas, United 
Kingdom). Radiography of the left hand was used to com-
pute soft-tissue thickness (difference between second finger 
proximal phalanx and total finger diameter), as is standard 
practice in clinical medicine, irrespective of the handedness 
of the patient (23).
Table 1. Indices of GH Action in Targeted Cohort of IGSF1-Deficient Male Patients
Patients Reference Data Source and Range P Value
n 21   
Age (y) 55.1 (21.8–85.2)   
BMI (kg/m2) 27.4 (24.4–34.6)   
Classified as acromegalic (%)a 52.4 19.1b 0.024
Finger soft-tissue thickness (SDS)c 1.1 (-0.3 to 2.3) (9) 0.001
Adult height SDS -0.4 (-1.7 to 1.0) (10, 11) 0.138
Head circumference (SDS) 1.3 (0.1–2.4) (12) <0.001
Fat mass index (SDS)d -0.08 (-0.94 to 4.95) (13) 0.175
Fat free mass index (SDS)d 0.40 (-2.42 to 1.92) (13) 0.793
IGF-1 (SDS) 1.0 (-0.1 to 2.9) In-house (age-dependent) 0.001
Free T4 (pmol/L) 14.3 (8.9–21.9) 12.0–22.0 pmol/L  
Prolactin (µg/L) 4.3 (1.4–15.4) 4.0–15.0 µg/L  
Testosterone (nmol/L) 14.3 (7.9–22.1) 8.0–31.0 nmol/L  
Cortisol (µmol/L) 0.355 (0.196–0.533) 0.100–0.600 µmol/L  
Testicular volume (SDS)e 2.9 (1.2–5.8) (14) <0.001
Data presented as number or median (P10-P90).
Abbreviations: BMI, body mass index; SDS, standard deviation score.
aBased on software analysis of facial photographs. 
bBased on 18 in-house age- and BMI-matched controls.
cN = 20. 
dCorrected for BMI and height, available n = 19 for fat mass index and n = 16 for fat-free mass index. 
eUltrasonographic volume of largest testis, n = 16.
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Evaluation of acromegalic facial characteristics. 
Frontal and lateral photographs of the face were analyzed 
as previously described using the Facial Image Diagnostic 
Aid software tool, which detects features of acromegaly with 
higher accuracy than a medical expert (15–17). Control images 
were obtained from 18 nonacromegalic-, age-, sex-, and BMI-
matched subjects (15–17). Images were individually classified 
by comparison with a training database comprising 64 
subjects with confirmed acromegaly and 230 control subjects 
using a maximum likelihood classifier, assigning images to 
acromegalic or nonacromegalic categories when the respective 
probability was greater than 50.0%. The probability of the 
subject belonging to either group according to the presence of 
acromegalic features was noted.
24-hour GH secretion patterns in patients. In 7 male 
patients, GH was measured at 10-minute intervals for 24 hours 
as described previously (18). Secretion and elimination rates 
were calculated using a validated automated deconvolution 
method (2, 18–20) and the orderliness and consistency of 
subpatterns were assessed with the approximate entropy (21, 
22). The outcome parameters of the deconvolution analysis 
were: pulse frequency (burst number/24 hour), half-life 
(minutes), secretion rates (µg/L/24 hour), and waveform shape 
(mode in minutes).
Mice: general characteristics
Igsf1Δexon1 and Igsf1Δ312 null mice were described previ-
ously. TSH synthesis is decreased in both genotypes of knock-
out mice. T4, T3, and TSH are variably affected in Igsf1∆exon1 
mice and equivalent to wild-type (WT) littermates in Igsf1∆312 
mice, although TRH action is impaired in the pituitaries of 
both species (6, 23). Here, heterozygous Igsf1Δexon1 or Igsf1Δ312 
females were crossed with C57BL6/J males (Igsf1Δexon1) or 
C57BL6/N males (Igsf1Δ312), and WT and IGSF1-deficient 
males were compared. Animals were housed in temperature- 
and light-controlled rooms (21-22°C, or 23°C, 12-hour light) 
with ad libitum access to food and water. No mice in this 
study were treated with synthetic thyroid hormone.
Murine auxology. Mice were weighed weekly from birth 
and body composition evaluated by time-domain nuclear 
magnetic resonance using a minispec Live Mice Analyzer 
LF90 (Bruker). Following euthanasia by carbon dioxide 
asphyxiation at age 44 weeks, nose to tail base length was 
recorded using a digital Vernier caliper (accuracy ± 0.1 mm), 
liver and kidneys were measured using a digital balance 
accurate to the nearest 1 mg, and the skeleton was harvested 
and either stored directly in 70% ethanol or fixed in 10% 
neutral buffered formalin and subsequently stored in 70% 
ethanol.
Murine skeletal analyses
Digital radiograph microradiography. Long bones 
and tail vertebrae (Ca6, Ca7) were fixed in 70% ethanol. 
Soft tissue was then removed and digital radiograph images 
were recorded at 10 µm resolution using a Faxitron MX20 
operating at 26  kV and 5x magnification (Qados, Cross 
Technologies plc, Sandhurst, Berkshire, UK). Bone length and 
relative bone mineral content were determined as previously 
described (24).
Micro-CT. Femurs were analyzed by Micro-CT (Scanco 
uCT50, Scanco Medical, Switzerland; 70 kV, 200 mA, 0.5-mm 
aluminum filter) and cortical (tissue volume, bone volume, 
cortical thickness, bone mineral density, medullary and 
total diameters) and trabecular (bone volume/tissue volume, 
trabecular number, thickness, spacing) parameters determined. 
Cortical bone was analyzed at a 10-µm voxel resolution in a 
1.5-mm region of interest (ROI) centered 56% of the length 
of the femur distal to the femoral head. Trabecular bone was 
analyzed at a 5-µm voxel resolution in a 1-mm long ROI 
beginning 100  µm proximal to the distal femoral growth 
plate. Scanco Medical 3D analysis software was used for all 
analyses and calculations (25). To generate high-resolution 
3-dimensional images, 16-bit tiff images were imported into 
32-bit Drishti (Australian National University Supercomputer 
Facility, http://anusf.anu.edu.au/Vizlab/drishti/) and ROIs 
were rendered using 64-bit Drishti.
Biomechanical testing. Bones were stored and tested in 
70% ethanol. Destructive 3-point bend testing of the femur 
and compression testing of caudal vertebrae 6 and 7 were 
performed using an Instron 5543 load frame and 100N 
and 500N load cells, respectively (Instron Limited, High 
Wycombe, Buckinghamshire, UK). Biomechanical variables 
of bone strength (yield load, maximum load, and stiffness) 
were determined from load-displacement curves as previously 
described (25, 26).
Skeletal preparations and histology. Limbs were fixed 
in 10% neutral buffered formalin for 24h and decalcified in 
10% EDTA for 21  days. Paraffin-embedded tibial sections 
were stained with van Gieson and Alcian blue and images 
of the proximal growth plates obtained. Growth plate 
dimensions were determined in ImageJ 1.41 software (http://
rsb.info-.nih.gov/ij/) with measurements in at least 4 separate 
positions. Mean values were calculated for the heights of the 
reserve zone, proliferative zone, hypertrophic zone, and total 
growth plate.
Murine IGF-1 and GH pituitary content 
measurements
IGF-1 was measured using a rat/mouse IGF-1 2-site 
immunoenzymometric assay (IDS Diagnostic, Tyne and Wear, 
UK). Blood was obtained by tail-bleed from mice with mean 
age 10 weeks, the morning after an overnight fast, using 
sodium-heparinized tubes. Pituitary GH content was meas-
ured during the light phase by ELISA in Igsf1Δ312 mice aged 
8 weeks and by radioimmunoassay in Igsf1Δexon1 mice as de-
scribed previously (27, 28).
Gh pituitary mRNA measurements. Total RNA was 
extracted from frozen, homogenized pituitary glands in 
TRIzol from Igsf1Δ312 mice aged 10 weeks. Following reverse 
transcription, quantitative PCR was performed using EvaGreen 
2X quantitative PCR MasterMix-S (Applied Biological 
Materials Inc., Richmond, British Columbia, Canada), and 
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Gh or Rpl19 primers, running each sample in duplicate, and 
normalizing to Rpl19 using the 2-ΔΔCt method (29).
Murine GH secretion profiling. Pulsatile GH secretion 
was measured in 6- and 9-week-old mice, as described by 
Steyn et al. (27) by collecting whole blood from the tail vein 
every 10 minutes for 6 consecutive hours beginning at 8:00 
am. GH was measured by ELISA.
Murine GHRH  test. An IP GHRH injection (mGRF; 
1  mg/kg; SCP0160, Sigma, Oakville, Canada) in saline was 
administered to mice aged 8 to 14 weeks, at 7:45 am with 
blood sampling for GH ELISA at baseline and 5, 10, 20, 40, 
and 60 minutes postinjection, as previously described by Steyn 
et al. (30).
Somatotrope quantitation. Pituitaries were harvested 
from mice aged 6 to 7 weeks. All cells from individual dissected 
pituitaries were seeded on poly-D-lysine–coated coverslips, 
then fixed with 4% paraformaldehyde. Immunostaining 
was performed using a primary rabbit anti-rat GH antibody 
(1:500; AFP5641801, NIDDK) and a secondary goat anti-
rabbit immunoglobulin IgG conjugated with Alexa fluor 488 
(1/1000; Molecular Probes, Invitrogen). GH-positive cells 
were calculated as the ratio of GH stained cells over total 
number of cells per coverslip.
Statistical comparison of group differences
Unless otherwise stated, group differences were compared 
using the 2-tailed independent Student t test or, in case the 
assumption of normality was not met (Shapiro-Wilk test), the 
Mann-Whitney U test. Categorical data were compared using 
the chi-square test (1-sample when compared with population 
data) or, when the expected count per cell was less than 5, 
Fisher’s exact test. Data were presented as mean ± SD or SEM, 
or, in case of non-normality, median (P10–P90). Correlations 
were assessed using the Pearson product-moment correlation 
coefficient or, for data that lacked a normal distribution, 
the Spearman rank correlation coefficient. Linear regression 
analysis was used to correct for age in the relation between 
years of untreated CCeH and BMI. Differences were con-
sidered statistically significant at P  <  0.05. Growth curves 
were analyzed using a linear mixed-effects model of weight 
versus age with genotypes as fixed effects and subjects (mice) 
as random factors, with a 2-way ANOVA to test the overall 
effect of genotype on growth followed by Tukey’s post hoc 
tests using GNU licensed R software for statistical computing 
and graphics (31).
Results
Clinical indices of GH action in IGSF1-deficient 
male patients
End-organ sequelae of GH excess are typified by the 
clinical phenotypes associated with gigantism or acro-
megaly, in which excessive GH secretion occurs either 
before or after fusion of the epiphyses, respectively. 
Indices of GH excess and its associated sequelae were 
first assessed in the targeted cohort of 21 IGSF1-deficient 
males aged 19 to 89 years (Table 1). Digital analysis of 
acromegaloid facial features classified 52.4% of adult 
male patients as acromegalic compared with 19.1% of 
controls (P  =  0.024). Acral growth analysis using left 
hand radiographs (data unavailable in 1 patient) showed 
left index finger soft-tissue thickness SDS to be ele-
vated in IGSF1-deficient patients. There was no correl-
ation between soft-tissue thickness SDS and either BMI 
(r = 0.280, P = 0.233), waist circumference (r =  -0.141, 
P = 0.554), or fat percentage (r =  -0.127, P = 0.592), 
suggesting this was not a consequence of obesity. Ten of 
20 available hand radiographs also demonstrated fea-
tures consistent with osteoarthritis, predominantly af-
fecting the carpometacarpal and interphalangeal joints. 
Affected patients were 58 to 89 years old, whereas those 
without osteoarthritis were 19 to 55 years old.
Individuals in the targeted cohort were also evaluated 
for symptoms of GH excess using direct questioning. 
One patient experienced a change in shoe size (increase 
of 1 full UK shoe size between the ages of 22 and 73 years 
old), and no one in ring size. Symptoms consistent with 
sleep apnea were present in 3 patients (the diagnosis 
was confirmed in 1), occasional acroparesthesia in 3 pa-
tients and oily skin in 6 patients. No one reported mal-
odorous sweating.
Head circumference SDS in the targeted cohort was 
found to be significantly increased (P < 0.001). Although 
all evaluated patients had CCeH, which may also cause 
macrocephaly, evaluation of head circumference in a 
larger group of IGSF1-deficient patients including avail-
able data from the previously published cohort (total 
n  =  41, ages 0.4-89.5  years) confirmed that this did 
not correlate with free thyroxine levels at the time of 
evaluation (P = 0.8) or with age at commencement of 
levothyroxine (P = 0.4). In these 41 patients, head cir-
cumference SDS was most markedly elevated in adults 
(median [P10-P90]: 1.25 SDS [0.2-2.35 SDS]) versus 
children (0.5 SDS [-0.02 to 1.1 SDS], P = 0.03, Fig. 1A).
Adult height has previously been reported to be 
normal in IGSF1 deficiency (1), and patients in the tar-
geted cohort also attained normal height, even when 
CCeH was first diagnosed in adulthood. No correlation 
was observed between years of untreated CCeH and 
adult height.
Four patients had been diagnosed with and treated 
for hypertension, all of whom were older than 60 years. 
In the remaining patients, median systolic and dia-
stolic blood pressure were within the World Health 
Organization recommended target range (125 mm Hg 
[P10-P90: 110-135 mm Hg] and 75 mm Hg [P10-P90: 
64-80 mm Hg], respectively). Two individuals had type 
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2 diabetes and 1 gave a history of prostate cancer and 
non-Hodgkin lymphoma. Lumbar bone mineral density 
was normal in 6 evaluated patients (mean, 1.14 ± 0.19 g/
cm2; T-score, 0.3 ± 1.2 SD).
Bioelectrical impedance analysis of body composition 
was used to evaluate lean and fat mass proportions in 
the targeted cohort because we hypothesized that lean 
mass may be increased and fat mass decreased in the 
context of GH excess. Most patients were overweight 
(BMI > 25 kg/m2 in 76%, with 19% exhibiting severe 
obesity [BMI > 30 kg/m2]), compared with prevalences 
of 54% and 14%, respectively, in the Dutch population 
(P < 0.001 and P = 0.53, respectively) (32). However, 
contrary to our hypothesis, both the fat mass index 
(median, -0.08 SDS; interquartile ratio, -0.83 to 1.59 
SDS; n = 19) and fat free mass index (0.40 SDS, -0.54 
to 1.01 SDS, n = 16) were comparable to that observed 
in a BMI-matched reference population (P = 0.175 and 
P  =  0.8, respectively). Years of untreated CCeH, cor-
rected for age, did not correlate with BMI of body 
composition.
Biochemical assessment of GH secretion in IGSF1-
deficient patients
Having established that IGSF1-deficient men exhibit 
acromegaloid characteristics, we next evaluated biochem-
ical parameters of GH secretion. Median serum IGF-1 SDS 
was significantly increased in the targeted cohort (Table 
1), and analysis of a larger group including available data 
from our previously published cohort (total n = 55) dem-
onstrated that the increased IGF-1 SDS was most marked 
in adults (Fig. 1B), as previously reported (4).
We then delineated GH load directly by assessing 
temporal GH secretion in 7 IGSF1-deficient adult males 
with comparable endocrine and phenotypic characteris-
tics to the rest of the targeted cohort, and 14 age-, sex-, 
and BMI-matched controls (Table 2). Median basal, 
pulsatile, and total GH secretion were significantly ele-
vated and exhibited a tendency to reduced secretory re-
gularity as evidenced by increased approximate entropy 
in 5 of the 7 subjects (P = 0.05) (Fig. 1C, Table 2). No 
differences were observed in pulse frequency, wave-
form shape, half-life, or Weibull gamma distribution (a 
marker of pulse regularity). There was no correlation of 
higher basal, pulsatile, or total GH secretion with adult 
height, lean body mass, or finger soft tissue thickness 
(data not shown).
We also evaluated GH increment following periph-
eral TRH injection in 12 patients. This test has been used 
in the diagnosis of acromegaly, where a paradoxical re-
sponse, defined as peak to basal GH ratio > 2 during a 
standard 200 µg TRH test, is observed in 50% to 75% 
cases (33). Seven of 12 evaluated adult IGSF1-deficient 
patients exhibited a paradoxical GH increase (Fig. 1D).
Figure 1. Measurements in IGSF1-deficient patients. (A) Head circumference SDS for 26 IGSF1-deficient children aged 1 to 16 years and 25 male 
adult patients aged 19 to 89.5 years. (B) IGF1 SDS in children aged 0.2 to 17.6 years (n = 27) and adults aged 18.1 to 88.1 years (n = 28). (C) 
24-hour GH secretion profiles in micrograms per liter distribution volume for adult patients (n = 7, dark gray) and controls (n = 14, light gray), 
mean and SEM. (D) GH in micrograms per liter at 20 minutes/basal GH during a 200 µg TRH stimulation test in 12 adult patients, with values 
above the dotted line representing a paradoxical increase (peak to basal GH ratio > 2 µg/L). (A and B) Bars denote mean and SEM, and broken 
lines denote the 0 SD reference value. P values were calculated using a Mann-Whitney U test. Abbreviations: SDS, standard deviation score; TRH, 
thyrotropin-releasing hormone. 
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GH biochemistry in IGSF1-deficient mice
We next evaluated biochemical indices of GH pro-
duction in male Igsf1∆exon1 mice to investigate whether 
somatotrope function in this model recapitulated the 
findings in IGSF1-deficient humans. Six-hour GH se-
cretion profiles in 6- and 9-week-old Igsf1∆exon1 and 
WT males were not significantly different (Table 3). 
However, median serum IGF-1 was significantly ele-
vated in 10-week-old Igsf1∆exon1 mice compared with 
WT animals (441 [P10-P90: 286-541] vs. 345 [P10-
P90: 220-463] ng/mL, P  =  0.03) (Fig. 2A), consistent 
with excess GH secretion.
We also used this model to further delineate pitu-
itary GH synthesis. Pituitary GH protein levels were 
elevated in 8-week-old Igsf1∆exon1 mice, although Gh 
mRNA levels were previously shown to be normal in 
this strain (Fig. 2B, (1)). Somatotrope numbers were 
comparable in Igsf1∆exon1 mice and WT controls aged 
6 to 7 weeks (Fig. 2C). In contrast, in a second IGSF1-
deficient model, Igsf1∆312 (6), pituitary Gh mRNA 
levels were elevated in 10-week-old mice but GH 
protein content was the same in 8-week-old WT and 
Igsf1∆312 mice (Fig. 2D, E).
A GHRH stimulation test showed a tendency to a 
larger GH response in Igsf1∆312 mice aged 8 to 14 weeks 
compared with WT controls, but responses in both 
groups were variable and the difference was not stat-
istically significant, as indicated by the area under the 
curve (Fig. 2F and inset).
Indices of growth hormone action in Igsf1∆exon1 
male mice
We next interrogated an acromegaloid phenotype 
in male Igsf1∆exon1 mice as a consequence of increased 
IGF-1 action. Comparison of Igsf1∆exon1 with WT 
males demonstrated a sustained 11% to 13% increase 
in body weight, which achieved significance by age 10 
weeks (P  =  0.035), persisted at 44 weeks (P  <  0.01) 
(Fig. 3A), and was associated with increased mean body 
length and kidney and liver weights at 44 weeks of age 
(Fig. 3B–D). Increased circulating IGF-1 levels from 
Igsf1∆exon1 mice at 10 weeks of age correlated with in-
creased hepatic weight of these animals at 44 weeks of 
age, while no correlation was observed in WT animals 
(Spearman rho = 0.6, P = 0.006, Fig. 3E).
Igsf1∆exon1 mice also exhibited globally increased skel-
etal dimensions at 44 weeks of age (Fig. 4A–E and Table 
4). Long bone architecture assessed by Faxitron X-ray 
skeletal microradiography (Fig. 4A) demonstrated a pro-
portionate increase in bone length in Igsf1∆exon1 mice 
(Fig. 4B, C). Using high-resolution microcomputed tom-
ography (Fig. 4D), we observed an increase in total tissue 
and bone volume (Fig. 4E), with a tendency for increased 
cortical thickness (Fig. 4F, Table 4), with comparable tra-
becular parameters and bone mineral density to controls 
(Table 4). Bones from Igsf1∆exon1 mice were stronger, with 
higher yield load noted for both femur and vertebrae, 
and higher vertebral maximum load, as predicted for 
normally mineralized bones with proportionately larger 
Table 3. Deconvolution of Plasma GH Blood Profiles in WT and Igsf1∆312 Mice
Mice P Valuea
 
WT Aged 6 
Wk
WT Aged 9 
Wk
Igsf1∆312 
Aged 6 Wk
Igsf1∆312 Aged 
9 Wk
Between 
Groups Time Time × Group
Pulse frequency 
(no./6 h)
4.6 ± 0.4 4.3 ± 0.3 4.7 ± 0.5 3.6 ± 0.4 0.58 0.048 0.23
Mode (min) 15.3 ± 1.0 16.3 ± 0.6 14.8 ± 0.9 15.2 ± 0.8 0.30 0.46 0.76
Slow half-life 
(min)
6.4 ± 0.6 6.2 ± 0.7 7.2 ± 0.6 7.1 ± 0.6 0.18 0.81 0.99
Basal secretion 
(ng/mL/6 h)
222 ± 127 313 ± 104 110 ± 28 171 ± 28 0.72 0.029 0.86
Pulsatile secretion 
(ng/mL/6 h)
539 ± 118 721 ± 148 801 ± 166 652 ± 140 0.52 0.96 0.27
Total secretion 
(ng/mL/6 h)
762 ± 226 1034 ± 219 912 ± 185 823 ± 157 0.62 0.62 0.32
Mean pulse mass 
(ng/mL)
132 ± 33 179 ± 35 186 ± 36 235 ± 60 0.37 0.33 0.68
ApEn 
(dimensionless)
0.791 ± 0.067 0.748 ± 0.069 0.804 ± 0.074 0.649 ± 0.067 0.61 0.056 0.28
Deconvolution analysis of plasma GH secretion profiles in male Igsf1Δexon1 and WT mice. Calculations were performed with an automated Matlab 
deconvolution program (34). Data are shown as mean ± SEM. 
Abbreviations: ApEn, approximate entropy; WT, wild-type.
aData were analyzed with the 2-way ANOVA for repeated measures, assessing differences between WT and Igsf1Δ312 mice (between groups), dif-
ferences between age 6 and 9 weeks (time), and the interaction between the effects of group and time (time × group). Where required, data were 
logarithmically transformed. The data at 6 and 9 weeks are from the same animals.
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internal and external diameters (Table 4). Despite the 
differences in final bone length, no difference in growth 
plate morphology was observed at P20.5 (Fig. 4G–I).
Lean body mass was also significantly increased 
in Igsf1∆exon1 mice aged 10 weeks and 44 weeks (Fig. 
5A, Table 4); however, there was also a tendency for 
Figure 2. (A) Plasma IGF-1 in 19 Igsf1∆exon1 and 18 WT mice, mean age 10 weeks (range, 8-11.9 weeks Igsf1∆exon1 and WT mice). (B) Pituitary 
GH protein content in adult male WT and Igsf1∆exon1 mice aged 8 weeks (n = 6 each). (C) GH-positive cells (GH stained cells/total number of cells) 
from WT (n = 4) or Igsf1∆exon1 mice (n = 3 age 6-7 weeks). (D) Relative pituitary Gh mRNA and (E) protein content in WT and Igsf1∆312 mice aged 
10 and 8 weeks of age, respectively (n = 11-13). (F) Mean GH response to GHRH in n = 12 WT and n = 16 Igsf1∆312 mice aged 8 to 14 weeks. 
Inset illustrates the area under the curve. Data presented as mean and SEM. P values were calculated using a Mann-Whitney U test or an unpaired, 
2-tailed student t test. Abbreviation: WT, wild-type.
Figure 3. Male Igsf1∆exon1 and WT mouse measurements at 44 weeks (n = 19-20 mice per genotype). (A) Longitudinal body weights (n = 8-20 
mice per genotype). (B) Body length, and (C) kidney and (D) liver weights at 44 weeks of age. (E) Correlation between liver weight at 44 weeks 
of age and plasma IGF-1 levels in Igsf1∆exon1 (n = 19) and WT (n = 18) mice aged 10 weeks. Line depicting the significant correlation in Igsf1∆exon1 
mice. (B-D) Data presented as mean and SEM. P values were calculated using a Mann-Whitney U test or an unpaired, 2-tailed Student t test. (E) P 
values were calculated using Spearman correlation analysis. Black circles: Igsf1∆exon1 mice; white circles: WT mice. Abbreviation: WT, wild-type.
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increased fat mass, which did not reach significance 
(Fig. 5B). As such, percentage fat and fat-free masses 
were not different between genotypes (Fig. 5C, Table 4).
Discussion
This is the first study to evaluate the role of IGSF1 in 
human or murine somatotrope function, and our find-
ings are consistent with end-organ sequelae of GH ex-
cess in both species. GH hypersecretion occurring after 
epiphyseal fusion may result in a constellation of clin-
ical features typically seen in acromegaly, including al-
tered facial appearance, characterized by prominence 
of the supraorbital ridge, broad nose, large lips, prog-
nathism, macroglossia, and coarsening of the facial 
features. Bony expansion and soft-tissue swelling may 
cause acral enlargement, and patients may report oily 
skin and hyperhidrosis. Systemic consequences of in-
creased GH levels include widespread complications 
such as sleep apnea and ventilatory dysfunction, insulin 
resistance and dyslipidemia, hypertension, ventricular 
hypertrophy and cardiomyopathy, as well as early-onset 
osteoarthritis. The risk of certain malignancies, espe-
cially colon and thyroid, may also be increased (35, 36). 
If the onset of hypersomatotropism precedes long bone 
epiphyseal fusion, the predominant effect of GH ex-
cess is to promote linear growth, resulting in increased 
height (37).
The most frequent manifestations of acromeg-
alic GH excess include characteristic facies and in-
creased acral growth, both of which were detected in 
our IGSF1-deficient patient cohort (35). The majority 
of patients were classified as acromegalic following 
digital analysis of facial photographs, substantiating 
Figure 4. Skeletal analyses in mice. (A-C) Faxitron X-ray skeletal microradiography and (D-F) microcomputed tomography analysis of skeletal 
architecture in male Igsf1∆exon1 and WT mice at 44 weeks of age (n = 19-20). (A) Representative images of femurs (Faxitron X-ray) from Igsf1∆exon1 
and WT mice. (B) Vertebral length, and (C) femoral and combined tibia and ulnar length were increased in Igsf1∆exon1 mice. (D) Representative 
images of femur (microcomputed tomography) from WT (top) and Igsf1∆exon1 (bottom) mice. (E) Femoral tissue volume and bone volume were 
increased in Igsf1∆exon1 mice. (F) External and internal femoral diameters and cortical thickness. (G) Proximal tibia growth plates from 10 WT and 
6 Igsf1∆exon1 mice, mean age P20.5, stained with Alcian blue (cartilage) and van Gieson (osteoid) with graphs (H, I) showing mean dimensions. 
Abbreviations: E, epiphysis; GP, growth plate; H, hypertrophic zone; PZ, proliferative zone; RZ, reserve zone; WT, wild-type. Error bars represent SD. 
Box-whisker plots: boxes extend from 25th to 75th percentiles, the horizontal line represents the median and the vertical bars the minimum and 
maximum values. Data presented as mean and SEM, P values were calculated using an unpaired, 2-tailed student t test.
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previous anecdotal reports of acromegalic facial fea-
tures in patients harboring IGSF1 mutations. Head cir-
cumference SDS was increased and did not correlate 
with thyroid status. Excessive acral growth was evi-
denced by elevated finger soft-tissue thickness SDS. 
Evaluation of Igsf1∆exon1 mice revealed globally in-
creased organ size and skeletal dimensions, also con-
sistent with GH-mediated effects.
Adult height was not increased in patients in this 
study, and IGSF1 deficiency has previously been asso-
ciated with normal adult stature (1, 3). The multiple 
childhood endocrinopathies in these patients may have 
complex influences on linear growth, with CCeH and 
transient GH deficiency predicted to have a negative im-
pact, whereas pubertal delay may predispose to greater 
adult height (38, 39). Additionally, the timing of GH 
hyperstimulation in IGSF1 deficiency may be crucial for 
determining the consequent end-organ sequelae. The 
age of onset of GH hypersecretion was not defined in 
this study; however, the more markedly elevated IGF-1 
levels and elevated head circumference SDS in adults 
compared with children and apparently paradoxical oc-
currence of childhood GH deficiency in a minority of 
cases would support a later onset GH hypersecretion. 
A gradually progressive adolescent or adult-onset GH 
excess may also explain why patients exhibit acromeg-
alic characteristics rather than increased height because 
acromegalic features develop as a result of bone expan-
sion after epiphyseal fusion has occurred without in-
creased linear growth.
Table 4. Auxological Parameters in Wild-Type and Igsf1∆exon1 Male Mice Aged 44 Weeks
Parameter Igsf1∆exon1 Wild-type P Value
Combined tibia and ulnar lengtha (mm) 16.2 (15.8–16.6) 15.6 (15.4–16.0) <0.0001
Femur length (mm) 16.8 ± 0.06 16.2 ± 0.06 <0.0001
Vertebral length (mm) 4.46 ± 0.02 4.28 ± 0.02 <0.0001
Femoral tissue volumea (mm3) 4.06 (3.74–4.27) 3.81 (3.52–4.04) 0.002
Femoral bone volume (mm3) 1.54 ± 0.02 1.46 ± 0.02 0.004
Femoral bone volume/tissue volume 0.38 ± 0.005 0.39 ± 0.005 0.2
Femoral cortical thicknessa (mm) 0.189 (0.179–0.200) 0.183 (0.177–0.196) 0.05
Bone mineral densitya (mgHA/cm3) 1007 (994–1069) 1012 (969–1060) 0.6
Number of trabeculae, distal tibia 3.45 ± 0.08 3.45 ± 0.07 1.0
Trabecular thickness, distal tibia (mm) 0.058 ± 0.001 0.057 ± 0.001 0.7
Femoral yield load (N) 14.22 ± 0.32 12.67 ± 0.32 0.002
Vertebral yield loada (N) 114.8 (105.1–134.7) 103.1 (88.7–115.1) 0.004
Femoral maximum load (N) 21.0 ± 0.5 20.3 ± 0.6 0.4
Vertebral maximum load (N) 135.5 ± 2.59 120.3 ± 2.46 0.0001
Femoral stiffness (N/mm) 127.6 ± 3.74 128.8 ± 3.16 0.8
Vertebral stiffness (N/mm) 452.8 ± 9.36 428 ± 11.3 0.1
Mean body length (mm) 104.6 ± 0.97 101.0 ± 1 0.02
Liver weight (g) 1.87 ± 0.09 1.60 ± 0.04 <0.01
Kidney weighta (g) 0.55 (0.51–0.67) 0.48 (0.42–0.57) <0.001
Lean mass (g) 10 wk 23.1 ± 0.37 20.7 ± 0.38 <0.0001
Fat mass (g) 10 wk 2.59 ± 0.18 2.29 ± 0.13 0.2
Lean mass (g) 44 wk 27.8 ± 0.44 24.6 ± 0.37 <0.0001
Fat mass (g) 44 wk 11.7 ± 0.85 9.8 ± 0.70 0.09
Percentage fat mass 44 wk 25.3 ± 1.27 24.3 ± 1.42 0.6
Percentage lean mass 44 wk 61.8 ± 1.13 62.4 ± 1.25 0.7
Auxological parameters in male Igsf1Δexon1 and wild-type (WT) mice aged 44 weeks with values from 19–20 mice of each genotype. Values represent 
mean  ± SEM with P values calculated using an unpaired, 2-tailed student t test or, afor parameters where either genotype was not normally distrib-
uted, median (P10-P90) with P values calculated using a Mann-Whitney U test.
Figure 5. Body composition of male Igsf1∆exon1 and WT mice at 44 weeks of age (n = 19-20 mice per genotype). (A) Lean mass in grams. (B) Fat 
mass in grams. (C) Percentage fat mass. Data presented as mean and SEM, P values were calculated using an unpaired, 2-tailed student t test.
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In contrast, Igsf1∆exon1 mice exhibit a global increase 
in body size and skeletal dimensions. This is highly likely 
to be driven by excess GH and is particularly notable in 
the context of CCeH, which usually results in growth 
retardation from the critical regulation of linear growth 
by thyroid hormones. Unlike humans, Igsf1∆exon1 mice 
exhibit increased body size and lean mass at 10 weeks 
of age, suggesting that GH production is already ele-
vated during the pubertal transition, before adulthood. 
Because murine long bone epiphyses do not fuse, per-
mitting continued slow, longitudinal growth into adult-
hood such continued growth, as well as an earlier onset 
GH excess may also explain the increase in murine skel-
etal dimensions, which is not observed in humans (40).
Although GH excess generally promotes increased 
lean and decreased fat mass, IGSF1-deficient patients 
exhibited increased BMI with appropriate body com-
position for an overweight population, without ob-
served increases in lean mass. These observations are 
consistent with the likely complex effects of IGSF1 
deficiency on body composition, to which increased 
GH action is but one contributing factor. In particular, 
hypothyroidism and delayed puberty associated with 
IGSF1 loss of function may predominantly increase fat 
mass proportions, thereby negating some of the effects 
of GH excess on body composition (41). Moreover, it is 
possible that bioelectrical impedance analysis of body 
composition is not sensitive enough for measuring 
minor changes in lean body mass (42). In contrast, in-
creased lean mass was detected in Igsf1∆exon1 mice, as 
expected in the context of their elevated IGF-1 levels. 
The reason for this difference between mice and hu-
mans was not explored; however, in contrast to humans, 
the murine gonadal axis seems relatively unaffected 
by IGSF1 deficiency, which may facilitate murine lean 
mass expansion in response to GH excess (23). There 
was a concomitant tendency to increased fat mass in 
Igsf1∆exon1 mice, which may have been due to untreated 
CCeH, or alternatively, a consequence of the globally 
increased body dimensions.
GH excess may also influence levels of thyroid 
hormone metabolites. Individuals harboring the 
p.L773P IGSF1 mutation have previously been noted 
to exhibit more markedly subnormal FT4 levels than 
FT3 levels, and decreased reverse T3 z scores (43). This 
biochemical pattern would be consistent with prefer-
ential deiodination of FT4 to FT3 at the expense of 
reverse T3 in order to mitigate tissue hypothyroidism. 
Differential, tissue-dependent regulation of deiodinase 
activity by GH has been proposed to produce a similar 
thyroid hormone signature, raising the possibility 
that peripheral effects of GH action also modulate 
thyroid hormone metabolism in the IGSF1 deficiency 
syndrome (44).
IGSF1-deficient patients in this study demonstrated 
clear biochemical evidence for increased GH secretion 
during 24-hour pulsatility studies, with increased basal, 
median, and pulsatile GH secretion. Additionally, me-
dian serum IGF-1 levels were increased. In Igsf1∆exon1 
mice, 6-hour GH secretion profiles were not significantly 
different from WT animals. However, interindividual 
variability was high and the highly dynamic nature of 
GH production may have precluded detection of modest 
differences over this relatively short sampling period. 
Such variability has also been described in the context 
of central hypothyroidism in this mouse line, where 
evaluation of some cohorts of Igsf1∆exon1 mice have 
shown decreased levels of serum T3 or T4, but in other 
cohorts, hormone levels have been comparable with WT 
measurements (1, 45). Indirect evidence for increased 
GH production in both Igsf1∆exon1 and Igsf1∆312 mice 
includes the detection of elevated pituitary GH levels 
in Igsf1∆exon1 mice and elevated pituitary Gh mRNA 
levels in Igsf1∆312. Metabolically divergent background 
strains for these models (C57BL/6J for Igsf1∆exon1 and 
C57BL/6N for Igsf1∆312 mice) may have contributed to 
the discordant mRNA and protein results (46).
Ascertainment of the underlying mechanism for the 
observed somatotrope neurosecretory hyperfunction 
was beyond the scope of this study. Because IGSF1 is ex-
pressed in rat hypothalamus, including ~19% of Ghrh-
expressing neurons, as well as in pituitary somatotropes, 
it may be implicated either in hypothalamic regulation 
of GH or play a somatotrope-specific role in GH pro-
duction or secretion (1, 3). Autonomous GH secretion 
is unlikely because patients exhibited normal Weibull 
gamma measurement and only borderline elevated ap-
proximate entropy. Moreover, although GH secretion is 
strikingly increased in humans, the 2- to 3-fold increase 
is distinct from acromegalic values, in which increases 
of up to 50-fold are observed (47). In Igsf1∆exon1 mice, 
IGF-1 and size increments were comparably modest and 
somatotrope numbers were normal.
It has previously been proposed that IGSF1 has a 
modulatory effect on pituitary hormone synthesis ra-
ther than being an essential component of hormone 
synthesis pathways (45). Such a function would be con-
sistent with the marked intra- and interfamilial pheno-
typic variability observed in humans harboring the same 
IGSF1 loss-of-function mutations and also within and 
between litters born to congenic Igsf1 knockout mouse 
strains (45). A recent study suggested that IGSF1 may 
inhibit TGFβ1 signaling, perhaps by interacting with 
the TGFβ type I  receptor, ALK5, thereby attenuating 
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TGFβ1’s suppression of Trhr1 expression in the basal 
state. Although further validation is required to sub-
stantiate this proposed model, these observations sup-
port a candidate modulatory mechanism for central 
hypothyroidism in IGSF1 deficiency (48).
By analogy with the effects of IGSF1 on thyrotrope 
function, a modulatory influence on GH production 
rather than an obligatory role in GH synthesis seems 
plausible. However, difficulties in proposing a mech-
anism for the other axes of anterior pituitary dysfunc-
tion in IGSF1 deficiency include the lack of information 
regarding the IGSF1 interactome, the protein’s lack of 
defined functional domains, and that its normal func-
tion remains unclear (45). GH pulsatile secretion is 
subject to a complex interplay between stimulatory 
and inhibitory influences. Hypothalamic GHRH exerts 
the main feedforward effect and hypothalamic som-
atostatin, as well as circulating GH and IGF-1, me-
diate feedback inhibition. Additionally, centrally acting 
neuromodulators may influence activity of somatostatin 
and GHRH-expressing neurons (49). Either decreased 
feedback inhibition or increased GHRH secretion or 
sensitivity could explain our observations in IGSF1 defi-
ciency. Future studies could include challenge with som-
atostatin analogues or IGF-1 to investigate the integrity 
of the pathways mediating GH inhibition, and human 
GHRH challenge to investigate whether the tendency to 
increased response in the mice is recapitulated in human 
patients. The observation that GH deficiency may occur 
in childhood, IGSF1 deficiency remains a conundrum in 
the context of the adult GH hypersecretion delineated 
in this study.
Although IGSF1 deficiency is associated with de-
creased TRH action in thyrotropes, the presence of 
a paradoxical GH response to TRH in patients does 
suggest that TRHR signaling is not globally de-
creased. However, the physiological significance of 
this observation with regard to the mechanism of GH 
hypersecretion in humans is unclear. TRH is known 
to have age- and endocrine environment-dependent 
effects on GH release in rats (50–52), but whether 
this translates to the human phenotype is unknown. 
A  paradoxical GH response to TRH may also be 
observed in nonacromegalic conditions (eg, depres-
sion, anorexia nervosa, untreated primary congenital 
hypothyroidism) where it has been hypothesized to 
reflect dysregulation of the normal dopaminergic 
or somatostatin-mediated inhibitory effects on GH 
release, supporting the argument that although a 
somatotrope-autonomous role for IGSF1 is possible, 
additional hypothalamic dysfunction may also con-
tribute to GH excess (53, 54).
The congenital nature of IGSF1 deficiency suggests 
that GH hypersecretion in affected patients is likely to 
persist lifelong, even if the onset occurs in adulthood. 
Therefore, although the 2- to 3-fold increase in GH se-
cretion is significantly less than that seen in acromegaly, 
the chronicity of this effect may be more marked than 
in patients with acquired somatotrope hyperfunction. 
Larger clinical studies are needed to determine the 
long-term consequences of this moderate, chronic GH 
excess. Metabolic parameters including lipid concen-
trations, fasting glucose, and insulin have previously 
been shown to be normal in a larger cohort of adult 
males with IGSF1 deficiency. However, C-peptide was 
increased in 40% of previously evaluated males; there-
fore, future studies warrant oral glucose tolerance 
testing, both to investigate glucose and insulin responses 
as well as the extent of GH suppression in response to 
a standard glucose load (3). Hand radiographs demon-
strated osteoarthritic features in 50% patients in the 
current study but the incidence of large joint or axial 
arthritis was not evaluated, and echocardiography was 
not performed to evaluate GH-induced cardiac con-
sequences. Additionally, the age range and relatively 
small numbers of patients in our study do not enable 
us to comment on the risk of malignancy in IGSF1-
deficient patients. Also, the magnitude of secreted GH 
levels and associated end-organ effects require evalu-
ation in heterozygous female IGSF1 mutation carriers 
who also exhibit elevated mean IGF-1 levels, and are 
less likely than their hemizygous male counterparts to 
exhibit CCeH with its potentially mitigating effect on 
GH secretion (3).
Our observations identify a novel role for IGSF1 in 
GH physiology and extend the phenotype of the IGSF1 
deficiency syndrome to include GH hypersecretion in 
affected adults with associated end-organ sequelae. 
A  similar phenotype was observed in Igsf1-deficient 
mice, although further studies are required to delin-
eate the underlying mechanism for these effects. Given 
the significant morbidity that may be associated with 
chronic GH excess, we suggest that clinical management 
of IGSF1-deficient patients should include vigilance for 
these long-term sequelae, especially in older adults.
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